AstraZeneca PLC
corporate_fare Company Profile
AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek monitors AZN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- US FDA Approves AstraZeneca's Imfinzi for Early Bladder Cancer, First New Therapy in 30 Years
- FDA Extends Review Period for AstraZeneca's Breast Cancer Drug Camizestrant
- FDA Approves AstraZeneca's Datroway for 1st-Line Metastatic Triple-Negative Breast Cancer
- Enhertu Recommended for EU Approval in HER2-Positive Metastatic Solid Tumours
- AstraZeneca's Camizestrant Recommended for EU Approval in 1st-Line Advanced Breast Cancer
Financial Snapshot
Insider Transactions
AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.